The products combine next-generation sequencing and analysis with the company's NGSengine software to provide high-resolution HLA genotyping information.
The genomics company reported revenues of $20.2 million for the quarter, driven by growth in its pharmaceutical services business and other non-VA customers.
The company's nucleic acid extraction kits have offered labs relief from COVID-19-related shortages of traditional silica-based bind-wash-elute assays.